MYELOMA

Feature

Novel Management Strategies for Myeloma Bone Disease

Therapeutic options for myeloma bone disease include bisphosphonates, immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies.

Latest News

Depth of Response Translates Into Real-World Benefit in Multiple Myeloma

By Christina Bennett, MS

Depth of response corresponded to overall survival and time to next treatment in real-world patients with relapsed/refractory multiple myeloma.

Dynamic Immune Biomarkers May Serve as Valuable Prognostic Factors for Multiple Myeloma

By

Patients who did not have immune dysregulation had higher overall survival compared with patients who had immune dysregulation.

Elotuzumab Combination Therapy May Improve Survival in Multiple Myeloma

By

Patients who received elotuzumab plus pomalidomide and dexamethasone demonstrated longer progression-free survival.

Thalidomide-Based Treatment May Be Viable for Patients With Multiple Myeloma

By

Bortezomib-based induction therapy is the current standard of care for patients with multiple myeloma, but thalidomide is a promising contender.

Cytarabine as a Chemotherapeutic Agent for Autologous Stem Cell Transplantation in Patients With Multiple Myeloma

By

Intermediate-dose cytarabine has been demonstrated to have high efficacy as a chemomobilization agent.

Pomalidomide, Cyclophosphamide, and Dexamethasone May Be Effective for Multiple Myeloma

By

Partial remission or better was observed in 85% of evaluable patients who received pomalidomide, cyclophosphamide, and dexamethasone.

PET-CT Scans May Be Useful in Predicting Prognosis in Patients With Newly Diagnosed Multiple Myeloma

By

PET-CT scans can reveal abnormalities such as bony lesions and extramedullary disease in patients with multiple myeloma.

Screening First-Degree Relatives of Multiple Myeloma Patients May Point to New Prevention Strategies

By

Screening first-degree relatives of patients with MM may be a viable prevention strategy.

Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed

By Christina Bennett, MS

First-degree relatives of patients with multiple myeloma were found to be at a higher risk of developing monoclonal gammopathy of undetermined significance.

Feasibility of Clinical Production of Autologous NKG2D CAR-T

By Randi Hernandez

The manufacturing approach yielded therapeutic doses of engineered T cells with activity against NKG2D ligands in acute myeloid leukemia and multiple myeloma.

Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma

By Joyce Pagan

An updated network meta-analysis found that a triplet regimen consisting of lenalidomide and dexamethasone plus an immunotherapeutic agent had better efficacy in terms of NRR, TTP, PFS, and OS than other regimens.

Elotuzumab May Improve Outcomes Without Negatively Impacting HRQoL in Multiple Myeloma

By James Nam, PharmD

Previous studies showed that elotuzumab plus lenalidomide and dexamethasone improved progression-free survival and response rates, but its impact on patient-reported outcomes is unknown.

Clarithromycin Plus Bortezomib May Be Ineffective, Toxic in Multiple Myeloma

By James Nam, PharmD

Researchers found that clarithromycin plus bortezomib does not confer any additional efficacy and is a toxic in patients with multiple myeloma.

Cancer-Related Fatigue May Predict Reduced Survival in Newly Diagnosed Multiple Myeloma

By James Nam, PharmD

Researchers investigated cancer-related fatigue in 16 patients with multiple myeloma who were treated with bortezomib, lenalidomide, or thalidomide.

Measurement of Excess Abdominal Fat, Not BMI, May Be a More Accurate Risk Factor for Blood Cancers

By Randi Hernandez

Abdominal adiposity was determined to be a better predictor of risk for hematological malignancies compared with BMI.

Evaluation of Available Frontline Induction Therapies for Multiple Myeloma

By James Nam, PharmD

There is paucity of comparative and efficacy information on novel agents used as frontline induction therapies in multiple myeloma.

Could a Blood Test Help Clinicians Diagnose Multiple Myeloma Earlier?

By Randi Hernandez

Levels of hemoglobin, combined with ESR, PV, and calcium values, were determined to be the blood parameters with the most diagnostic value in multiple myeloma.

A Novel Formulation of Melphalan May Not Prevent Complications Post-ASCT in Multiple Myeloma

By James Nam, PharmD

High-dose melphalan is a frequently before ASCT in MM, but is associated with high rates of adverse events.

PVX-410 Vaccine May Delay Disease Progression of Smoldering Multiple Myeloma

Reinforcing the immune system with a the PVX-410 vaccine may prevent or slow progression to multiple myeloma.

Prescription Drug Coverage in Medicare Part D Is Tied to a Survival Advantage in Myeloma

By Randi Hernandez

Drug coverage status influenced the treatments that were selected for Medicare beneficiaries with myeloma and, consequently, their overall survival.

SIGN UP FOR FREE E-NEWSLETTERS